Skip to main navigation

MoonLake

e: info@moonlaketx.com

About us
Science
Investor relations

Site - Main

About us
Science
Investor relations

e: info@moonlaketx.com

INVESTOR RELATIONS

Press Releases

Year

All News
2024
2023
2022
2021

Nov 13 2024

MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis

Read More +

Nov 7 2024

MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update

Read More +

Sep 9 2024

MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11

Read More +

Aug 7 2024

MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11

Read More +

Jun 10 2024

MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis

Read More +

May 16 2024

MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa

Read More +

May 7 2024

MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update

Read More +

Apr 10 2024

MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions

Read More +

Mar 10 2024

MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day

Read More +

Mar 4 2024

MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024

Read More +

Pagination

Current page 1
Page 2
Page 3
Page 4
Page 5
Next page
Last page

Displaying 1 - 10 of 41

Site - Investor Tools

Contact Us

MoonLake Immunotherapeutics AG Dorfstrasse 29, 6300 Zug, Schweiz/Switzerland

e: info@moonlaketx.com
media: media@moonlaketx.com
IR: ir@moonlaketx.com

Quick Links

Home
About us
Team
Science
Pipeline

Therapeutic focus
Investor relations
Careers
Privacy policy

© 2024 - MoonLake Immunotherapeutics

Privacy Policy